Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdosteine add-on therapy for acute exacerbations in pediatric bronchiectasis
ACTRN12624001381572Phase 4Not yet recruiting
- Sponsor
- Queensland University of Technology
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in bronchiectasis comparing Erdosteine add-on therapy with Placebo add-on therapy (2 arms). Primary endpoint: Duration of symptoms of respiratory exacerbation. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
erdosteine
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on ACTRN12624001381572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001381572.